{"entity":{"id":"nct06751329","kind":"trial","name":"A Study of DM002 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of DM002 in ovarian cancer, prostate cancer, endometrial cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by Xadcera Biopharmaceutical (Suzhou) Co., Ltd., now recruiting.","summary":"A Study of DM002 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06751329 by Xadcera Biopharmaceutical (Suzhou) Co., Ltd., with 280 participants planned, started 2025-02-17 and due to reach its primary completion in 2027-10-08. Interventions recorded: DM002.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06751329","url":"https://clinicaltrials.gov/study/NCT06751329"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","prostate","endometrial","colorectal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06751329","phase":"1/2","setting":"A Phase I/IIa, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors","sponsor":"Xadcera Biopharmaceutical (Suzhou) Co., Ltd.","enrolled":280,"outcomes":[]},"route":"/trials/nct06751329/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}